Abstract 2535: Development of Claudin 18.2 IHC 14G11 pharmDx as a clinical trial assay for the clinical development of anti-claudin 18.2 monoclonal antibody osemitamab (TST001) in gastric and gastroesophageal junction adenocarcinoma
Hayley Alderson(Agilent Technologies (United States)), Emin Oroudjev(Agilent Technologies (United States)), Xinlai Yao(Bioscience (China)), Xueming Qian(Xi'an Jiaotong University), Donna Kell(Agilent Technologies (United States)), Katie Lefley(Agilent Technologies (United States)), Lesly Fregoso(Agilent Technologies (United States)), Dan Castellanos-McKenney(Agilent Technologies (United States)), Achintya Bharadwaj(Agilent Technologies (United States)), Caroline Germa(Novartis (United States)), Li Xu(Fujian Medical University), Siena Tabuena-Frolli(Agilent Technologies (United States))
Cited by 2
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Maytansinoid-Antibody Conjugates Induce Mitotic Arrest by Suppressing Microtubule Dynamic Instability
|Molecular Cancer Therapeutics|2010|161
Molecular Aspects of Boundary Lubrication by Human Lubricin: Effect of Disulfide Bonds and Enzymatic Digestion
|Langmuir|2007|149
Gremlin1 is a therapeutically targetable FGFR1 ligand that regulates lineage plasticity and castration resistance in prostate cancer
|Nature Cancer|2022|71
Recycling and direct regeneration of valuable cathode materials from spent Li-ion batteries: a comprehensive review
|Journal of Materials Chemistry A|2025|40